Skip to main content
Clinical Trials/NCT05549765
NCT05549765CompletedNot Applicable

The Effectiveness and Safety of Pharmacopuncture on Inpatients With Tension Headache Caused by Traffic Accidents: A Pragmatic Randomized Controlled Trial

Jaseng Medical Foundation1 site in 1 country80 target enrollmentStarted: September 8, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
80
Locations
1
Primary Endpoint
Numeric Rating Scale(NRS) of headache

Study Overview

Brief Summary

This study is a double blind, randomized controlled trail. condition/disease: acute tension headache treatment/intervention: Pharmacopuncture

Detailed Description

"Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.

This treatment is known to be an important part of Korean medicine treatment. However, there has been no specific value for the effect of this treatment.

Therefore, the investigators are going to conduct a randomized controlled trials to verify the efficacy and safety of Pharmacopuncture. From September 2022 to December 2023, the investigators are going to collect 80 inpatients who are suffering from Tension headache with the numeric rating scale(NRS) over 5 after injury by acute traffic accident(TA). For experimental group(n=40), the investigators will conduct Pharamacopuncture on suboccpital muscle three times(on 2nd, 3rd and 4th day of hospitalization) and other Korean medical treatment. For control group(n=40), just Korean medical treatment except Pharamacopuncture on suboccpital muscles will be conducted.

For these two groups, the investigators will compare Numeric Rating Scale(NRS) of headache, NRS of Neck pain, Headache Disability Index(HDI), Headache Impact Test-6(HIT-6), EuroQol 5-Dimension (EQ-5D-5L) and Patient Global Impression of Change (PGIC)."

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
19 Years to 69 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients who needs hospitalization due to acute tension headache that occurred within 7 days after traffic accident
  • •Patients with NRS ≥ 5 for headache
  • •Patients aged 19-69 years on the date they sign the consent form
  • •Patients who provide consent to participate in the trial and return the informed consent form

Exclusion Criteria

  • •Patients with a specific serious disease that may cause headache: malignancy, cerebral hemorrhage, dural hematoma, etc.
  • •Patients with progressive neurological deficits or with severe neurological symptoms- Patients who have had surgery or procedures within the last three weeks
  • •The cause of pain is due to soft tissue disease, not the nerve system disease: trigeminal neuralgia, glossopharyngeal neuralgia, etc.
  • •Patients with other chronic conditions that may interfere with the interpretation of the therapeutic effects or results: cardiovascular disease, kidney disease, diabetic neuropathy, dementia, epilepsy, etc.
  • •Patients who are taking steroids, immunosuppressants, mental illness drugs, or other drugs that may affect the results of the study
  • •If pharmacopuncture and acupuncture is inadequate or unsafe: patients with hemorrhagic, receiving anticoagulants, severe diabetes and cardiovascular disease
  • •Patients who are pregnant or planning to become pregnant
  • •Patients with a serious mental illness
  • •Patients who are participated in clinical trials other than observational studies without therapeutic intervention.
  • •Patients who are difficult to complete the research participation agreement
  • •Other patients whose participation in the trial is judged by a researcher to be problematic

Arms & Interventions

Pharmacopucture on suboccipital muscles

Experimental

The Pharmacopucture group will recieve 3 sessions of Pharmacopucture on suboccipital muscles; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience are going to conduct the pharmacopucture.

The Pharmacopucture group will also be treated with other Korean medical treatment everyday: acupuncture, chuna and Korean herbal medicine.

Intervention: Pharmacopuncture (Procedure)

Pharmacopucture on suboccipital muscles

Experimental

The Pharmacopucture group will recieve 3 sessions of Pharmacopucture on suboccipital muscles; on second, third, fourth day after hospitalization. A trained doctor of Korean medicine with at least 3 years of clinical experience are going to conduct the pharmacopucture.

The Pharmacopucture group will also be treated with other Korean medical treatment everyday: acupuncture, chuna and Korean herbal medicine.

Intervention: Korean medical treatment (Procedure)

Korean medical treatment

Active Comparator

The control group will be received Korean medical treatment everyday after hospitalization: acupuncture(except on suboccipital parts), chuna, pharmacoacupuncture and Korean herbal medicine

Intervention: Korean medical treatment (Procedure)

Outcomes

Primary Outcomes

Numeric Rating Scale(NRS) of headache

Time Frame: Change from baseline NRS at 4 days

The extent of headache and discomfort will be assessed by using NRS. NRS is a pain scale in which the patient indicates their subjective pain as a whole number from 0 to 10. The participant is asked to report their headache and discomfort using NRS, where 0 indicates 'no pain or discomfort' and 10 indicates 'the most severe pain and discomfort imaginable'.

Secondary Outcomes

  • EuroQol 5-Dimension 5-Level (EQ-5D-5L)(Baseline(day2), day4, day of discharge(up to 14days), week 8)
  • Headache Disability Index(HDI)(Baseline(day2), day4, day of discharge(up to 14days), week 8)
  • Patient Global Impression of Change(PGIC)(day4, day of discharge(up to 14days), week 8)
  • Numeric Rating Scale(NRS) of Neck pain(Baseline(day2), day3, day4, day of discharge(up to 14days), week 8)
  • Headache Impact Test-6(HIT-6)(Baseline(day2), day4, day of discharge(up to 14days), week 8)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

In-Hyuk Ha, KMD

Director

Jaseng Medical Foundation

Study Sites (1)

Loading locations...

Similar Trials